Navigation Links
BRAF inhibitor treatment causes melanoma cells to shift how they produce energy
Date:3/8/2013

A multi-institutional study has revealed that BRAF-positive metastatic malignant melanomas develop resistance to treatment with drugs targeting the BRAF/MEK growth pathway through a major change in metabolism. The findings, which will be published in Cancer Cell and have been released online, suggest a strategy to improve the effectiveness of currently available targeted therapies.

"We were surprised to find that melanoma cells treated with the BRAF inhibitor vemurafenib dramatically change the way they produce energy to stay alive," says David E. Fisher, MD, PhD, chief of Dermatology at Massachusetts General Hospital (MGH) and a co-corresponding author of the Cancer Cell paper. "While current BRAF inhibitor treatment is a major improvement shrinking tumors in most patients and extending survival for several months patients eventually relapse. So there is an ongoing need to improve both the magnitude and durability of these responses."

In about half the cases of malignant melanoma the most deadly form of skin cancer tumor growth is driven by mutations in the BRAF gene. Research by investigators at the MGH Cancer Center and elsewhere has shown that treatment with drugs that block BRAF activity temporarily halts tumor growth. Combining a BRAF inhibitor with a drug that targets MEK, another protein in the same growth pathway, strengthens and extends the antitumor response. The current study was designed to investigate how BRAF inhibition changes metabolic activity within melanoma cells and to find other possible treatment targets.

The most common way that cells convert glucose into energy is called oxidative phosphorylation and largely relies on the activity of the cellular structures called mitochondria. Many cancer cells use an alternative mechanism that produces the energy compound ATP without involving mitochondria. A series of experiments by the MGH team revealed that the elevated BRAF activity in BRAF-positive melanoma cells suppresses oxidative phosphorylation by reducing expression of a transcription factor called MITF. Suppressing production of MITF reduced levels of a protein called PGC1α that regulates the generation and function of mitochondria. But melanoma cells treated with a BRAF inhibitor showed elevated MITF activity, along with increased expression of oxidative phosphorylation genes and greater numbers of mitochondria. By switching to oxidative phosphorylation to supply the energy they need, the tumor cells increased their ability to survive in spite of BRAF inhibitor treatment.

"These findings suggest that combination treatment with mitochondrial inhibitors could improve the efficacy of BRAF inhibitors in malignant melanoma," says Fisher, the Wigglesworth Professor of Dermatology at Harvard Medical School. "Several small molecules that target mitochondrial metabolism have been identified by investigators here at the MGH and elsewhere, and laboratory investigations of specific combinations of BRAF inhibitors with mitochondrial antagonists are currently underway."


'/>"/>

Contact: Michelle Marcella
mmarcella@partners.org
617-724-2755
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
2. VyGone Inhibitor Zapper: The Brand New Solution For the Safe Treatment Of Sores, Warts and Herpes
3. Inhibitors of shuttle molecule show promise in acute leukemia
4. Leukemia inhibitory factor may be a promising target against pancreatic cancer
5. Uncommon BRAF mutation in melanoma sensitive to MEK inhibitor drug therapy
6. Preclinical data support ongoing clinical trials testing IDO inhibitors as a treatment for cancer
7. PARP inhibitors may have clinical utility in HER2-positive breast cancers
8. New mechanism of action for PARP inhibitors discovered
9. PI3-kinase and PARP inhibitor combo may offer new treatment option for triple-neg breast cancers
10. Scientists at Mainz University identify inhibitor of myelin formation in the central nervous system
11. New small molecule inhibitor could be a safe and first-line treatment for metastatic breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/12/2019)... ... November 12, 2019 , ... ... study. With increasing site activation cycle times, extended contract negotiations and 80 percent ... an area of clinical operations that’s ripe for improvement. Following an overview of ...
(Date:11/11/2019)... IRVINE, Calif. (PRWEB) , ... November 11, 2019 ... ... providers of business support services to dental groups in the United States, today ... serving the community of Lodi, CA. , Patients will enjoy convenient hours, comfortable ...
(Date:11/11/2019)... ... 11, 2019 , ... Dr. John V. Prunskis, co-founder and co-Medical Director of ... Pain Management Best Practices Task Force (Pain Task Force) met last Monday with Joe ... to the HHS Pain Task Force’s final report that was submitted to Congress in ...
(Date:11/9/2019)... YORK (PRWEB) , ... November 09, 2019 , ... On ... the story of a retired and disabled 64-year-old New Yorker who recently faced homelessness. ... moved her into transitional housing until she found a new home in an assisted-living ...
(Date:11/7/2019)... ... 07, 2019 , ... Understanding UDI in EU Device Regulations, An FDAnews Webinar, ... Are EU device and IV diagnostics sales in jeopardy? , It’s not a trick ... ahead, and many device and diagnostics makers simply aren’t prepared. , Not yet anyway. ...
Breaking Medicine News(10 mins):
(Date:11/11/2019)... , ... November 11, 2019 , ... Over 60 schools ... telehealth service in place. The program is designed to provide virtual mental health care ... storm that struck the region in October of 2018 [1]. , “This initiative by ...
(Date:11/11/2019)... , ... November 11, 2019 , ... The Naderi Center ... America health care practice POS, point of sale, website for providing the highest level ... Naderi Center for Cosmetic Surgery Specialists uses advanced financial technology in their daily business ...
(Date:11/11/2019)... ... ... The Advocator Group, LLC, part of Brown & Brown Inc., is honored ... the Boston Globe Magazine. This recognition has been earned for the fourth consecutive year ... , The rankings for the Top 100 Women-Led Businesses in each state are ...
Breaking Medicine Technology: